◀ Back to NOS3

NOS3 — VIP

Text-mined interactions from Literome

Mourad et al., Am J Physiol Gastrointest Liver Physiol 2006 (Colitis...) : The effects of 1 ) tetrodotoxin ( TTX ), 2 ) benzylalkonium chloride ( BAC ), 3 ) capsaicin, 4 ) vasoactive intestinal polypeptide (VIP) antagonism, 5 ) nitric oxide ( NO ) synthase ( NOS ) inhibition , and 6 ) 5-hydroxytryptamine type 3 and 4 ( 5-HT(3) and 5-HT(4) ) receptor antagonism on the changes in fluid movement were investigated
Sabbatini et al., Eur J Pharmacol 2007 (Proteinuria) : However, CNP response was unaltered by cholecystokinin and vasoactive intestinal peptide receptor blockade or by nitric oxide synthase inhibition
Zhang et al., J Physiol Sci 2010 : Western blot analysis revealed that VIP increased the phosphorylation of eNOS at Ser 1177, but did not affect the overall expression of eNOS
Amato et al., Am J Physiol Gastrointest Liver Physiol 2010 : GLP-2 inhibitory effect was not affected by N ( ? ) -nitro-l-arginine methyl ester ( a nitric oxide synthase inhibitor ), apamin ( a blocker of small conductance Ca ( 2+ ) -dependent K ( + ) channels ), or [ Lys1,Pro2,5,Arg3,4,Tyr6 ] VIP ( 7-28 ) ( a VIP receptor antagonist ), but it was prevented by atropine or pertussis toxin ( PTX ), a G ( i/o ) protein inhibitor
González et al., J Cereb Blood Flow Metab 1997 : Neuronal nitric oxide synthase activation by vasoactive intestinal peptide in bovine cerebral arteries